BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer This phase I/II, open-label, ...
Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...
Platelets play an essential role in wound healing. Underproduction can cause devastating bleeding, while overproduction increases the deadly risk of thromboses. Maintaining a constant level of ...
Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...
“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...
Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...
Age-related macular degeneration in individuals with clonal hematopoiesis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results